News

Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.

 

Antibiotic Alternative for Cattle Approved for Sale in Canada by the Canadian Food Inspection Agency

Amplimune™ has received approval for sale in Canada by the Canadian Food Inspection Agency. The Company believes this is the first antibiotic alternative therapy for livestock to receive Canadian regulatory approval.

dog running in the grass

NovaVive Inc. Summarizes Canine Cancer Data Presented at World Veterinary Cancer Congress

The results of clinical studies using MCW formulations in ameliorating neutropenia and inducing serum cytokine synthesis were presented at the 3rd World Veterinary Cancer Congress (WVCC) in May, 2016 in Brazil.

person working in a lab

NovaVive Inc. Announces its Canine Cancer Development Plan

Building on its safe and effective treatment for canine mammary cancer (Immunocidin®), NovaVive is targeting canine hemangiosarcoma, chemotherapy-induced neutropenia, and palliation as new indications.

mare with foal in field

Settle®: A Regulator-Approved Antibiotic Alternative for Treating Equine Endometritis

NovaVive offers an alternative to antibiotics for the treatment of equine endometritis: Settle®. This product is fully approved by regulators in the U.S. and Australia for endometritis caused by Streptococcus zooepidemicus.

close-up of horse's face

U.S. and Canadian Regulator-Approved Immunotherapeutic Available for Equine Sarcoid Tumors

NovaVive's cancer immunotherapy, Immunocidin(R), received USDA and CFIA approval for the treatment of equine sarcoid tumors in February, 2016. The Company believes that this is North America's first approved sarcoid therapy.

New Canadian Animal Health Company

Belleville, Ontario – Graeme McRae, Founder and Chairman Emeritus of Bioniche Life Sciences Inc., has founded NovaVive Inc., a Belleville, Ontario, Canada-based company that is acquiring and developing specialty, imm...

Sign up to stay up-to-date with NovaVive news.